Janus kinase 2

JAK2
Gene ontology
Molecular function	SH2 domain binding kinase activity signaling receptor binding ATP binding growth hormone receptor binding interleukin-12 receptor binding metal ion binding heme binding histone kinase activity (H3-Y41 specific) transferase activity histone binding protein binding protein tyrosine kinase activity protein kinase binding nucleotide binding non-membrane spanning protein tyrosine kinase activity identical protein binding protein kinase activity protein C-terminus binding type 1 angiotensin receptor binding acetylcholine receptor binding phosphatidylinositol 3-kinase binding insulin receptor substrate binding peptide hormone receptor binding
Cellular component	cytoplasm cytosol membrane extrinsic component of cytoplasmic side of plasma membrane caveola cytoskeleton nucleus nuclear matrix endosome lumen membrane raft endomembrane system nucleoplasm plasma membrane focal adhesion postsynapse glutamatergic synapse
Biological process	negative regulation of neuron apoptotic process intrinsic apoptotic signaling pathway in response to oxidative stress adaptive immune response interferon-gamma-mediated signaling pathway negative regulation of DNA binding tumor necrosis factor-mediated signaling pathway protein phosphorylation positive regulation of phosphoprotein phosphatase activity growth hormone receptor signaling pathway positive regulation of interleukin-1 beta production positive regulation of DNA binding mesoderm development activation of cysteine-type endopeptidase activity involved in apoptotic process negative regulation of cell population proliferation apoptotic process regulation of apoptotic process positive regulation of cell activation mammary gland epithelium development extrinsic apoptotic signaling pathway axon regeneration activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway response to antibiotic positive regulation of nitric-oxide synthase biosynthetic process response to oxidative stress response to tumor necrosis factor response to interleukin-12 positive regulation of cell differentiation positive regulation of tumor necrosis factor production positive regulation of peptidyl-tyrosine phosphorylation erythrocyte differentiation protein autophosphorylation platelet-derived growth factor receptor signaling pathway positive regulation of cell-substrate adhesion positive regulation of growth hormone receptor signaling pathway G protein-coupled receptor signaling pathway cell differentiation growth hormone receptor signaling pathway via JAK-STAT positive regulation of inflammatory response phosphorylation immune system process positive regulation of DNA-binding transcription factor activity negative regulation of cardiac muscle cell apoptotic process actin filament polymerization response to lipopolysaccharide regulation of inflammatory response peptidyl-tyrosine autophosphorylation enzyme linked receptor protein signaling pathway positive regulation of insulin secretion receptor signaling pathway via JAK-STAT intracellular signal transduction negative regulation of cell-cell adhesion mineralocorticoid receptor signaling pathway negative regulation of heart contraction positive regulation of cell migration positive regulation of cytosolic calcium ion concentration positive regulation of nitric oxide biosynthetic process blood coagulation response to hydroperoxide MAPK cascade regulation of interferon-gamma-mediated signaling pathway regulation of cell population proliferation positive regulation of cell population proliferation hormone-mediated signaling pathway positive regulation of apoptotic process positive regulation of phosphatidylinositol 3-kinase signaling peptidyl-tyrosine phosphorylation cell migration signal transduction positive regulation of epithelial cell apoptotic process positive regulation of growth factor dependent skeletal muscle satellite cell proliferation innate immune response negative regulation of cell death positive regulation of vascular associated smooth muscle cell proliferation positive regulation of tyrosine phosphorylation of STAT protein activation of Janus kinase activity tyrosine phosphorylation of STAT protein interleukin-12-mediated signaling pathway cytokine-mediated signaling pathway interleukin-23-mediated signaling pathway interleukin-6-mediated signaling pathway interleukin-27-mediated signaling pathway interleukin-35-mediated signaling pathway chromatin organization regulation of receptor signaling pathway via JAK-STAT regulation of nitric oxide biosynthetic process positive regulation of Ras protein signal transduction modulation of chemical synaptic transmission postsynapse to nucleus signaling pathway positive regulation of cold-induced thermogenesis microglial cell activation positive regulation of MHC class II biosynthetic process
Sources:Amigo / QuickGO

Ensembl				ENSG00000096968	ENSMUSG00000024789
UniProt	O60674	Q62120
RefSeq (mRNA)	NM_004972 NM_001322194 NM_001322195 NM_001322196 NM_001322198 NM_001322199 NM_001322204	NM_001048177 NM_008413
RefSeq (protein)	NP_001309123 NP_001309124 NP_001309125 NP_001309127 NP_001309128 NP_001309133 NP_004963	NP_001041642 NP_032439
Location (UCSC)	Chr 9: 4.98 – 5.13 Mb	Chr 19: 29.23 – 29.29 Mb
PubMed search	[3]	[4]

Wikidata

View/Edit Human

View/Edit Mouse

Janus kinase 2 (commonly called JAK2) is a

The distinguishing feature between janus kinase 2 and other JAK kinases is the lack of Src homology binding domains (SH2/SH3) and the presence of up to seven JAK homology domains (JH1-JH7). Nonetheless the terminal JH domains retain a high level of homology to tyrosine kinase domains. An interesting note is that only one of these carboxy-terminal JH domains retains full kinase function (JH1) while the other (JH2), previously thought to have no kinase functionality and accordingly termed a pseudokinase domain, has since been found to be catalytically active, albeit at only 10% that of the JH1 domain.^[7][8]

Loss of Jak2 is lethal by embryonic day 12 in mice.^[9]

JAK2

for which complete genome data are available.

Clinical significance

JAK2 gene fusions with the TEL(ETV6) (

Mutations in JAK2 have been implicated in

, because the receptors for these growth factors require JAK2 for signal transduction. Jak2 mutation, when demonstrable, is one of the methods of diagnosing polycythemia vera.^[15]

Interactions

Janus kinase 2 has been shown to

with:

Prolactin signals through JAK2 are dependent on STAT5, and on the RUSH transcription factors.^[59]

See also

• Janus kinase inhibitor, medical drugs under development
• Ruxolitinib

References

Further reading

• Berger R (May 2006). "[A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders]". Pathologie-Biologie. 54 (4): 182–4.
  PMID 16084028
  .
• Pargade V, Darnige L, Gaussem P (2006). "[Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera]". Annales de Biologie Clinique. 64 (1): 3–9.
  PMID 16420986
  .
• Staerk J, Kallin A, Royer Y, Diaconu CC, Dusa A, Demoulin JB, Vainchenker W, Constantinescu SN (March 2007). "JAK2, the JAK2 V617F mutant and cytokine receptors". Pathologie-Biologie. 55 (2): 88–91.
  PMID 16904848
  .
• Hsu HC (March 2007). "Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders". Journal of the Chinese Medical Association. 70 (3): 89–93.
  S2CID 33300937
  .

External links

• Janus+Kinase+2 at the U.S. National Library of Medicine Medical Subject Headings (MeSH)